Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaT Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisOther: Questionnaire Administration
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 475
- Registration Number
- NCT03007147
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Mercaptopurine Therapy in Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2020-01-07
- Target Recruit Count
- 136
- Registration Number
- NCT02910245
- Locations
- 🇳🇱
Meander MC, Amersfoort, Netherlands
🇳🇱Amstelland Hospital, Amsterdam, Netherlands
🇳🇱OLVG Oost, Amsterdam, Netherlands
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT02894645
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- B Acute Lymphoblastic Leukemia, BCR-ABL1-LikeB Acute Lymphoblastic LeukemiaCentral Nervous System LeukemiaTesticular Leukemia
- Interventions
- Other: Laboratory Biomarker AnalysisRadiation: Radiation Therapy
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸Mission Hospital, Asheville, North Carolina, United States
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- Procedure: Cranial irradiationProcedure: Stem cell transplantation
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1000
- Registration Number
- NCT02881086
- Locations
- 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT02877303
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
LBL-2016 for Children or Adolescents in China
- Conditions
- Lymphoblastic Lymphoma
- Interventions
- Drug: 6-mercaptopurine,MethotrexateDrug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, MethotrexateDrug: Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginaseDrug: Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Children's Cancer Group, China
- Target Recruit Count
- 150
- Registration Number
- NCT02845882
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, China
🇨🇳West China Second University Hospital, Chengdu, China
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Conditions
- B Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT02828358
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
- Conditions
- ALL
- Interventions
- Drug: TITProcedure: Autologous transplantationProcedure: Allo transplantation
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT02776605
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT02723994
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.